• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

    4.570 +0.500 (+12.29%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 781,004
    Open 4.450
    Bid (Size) 4.570 (5,000)
    Ask (Size) 4.640 (2,800)
    Prev. Close 4.070
    Today's Range 4.421 - 4.892
    52wk Range 1.810 - 4.892
    Shares Outstanding 60,533,064
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via GlobeNewswire
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill

    Performance

    YTD
    +133.2%
    +133.2%
    1 Month
    +134.4%
    +134.4%
    3 Month
    +64.4%
    +64.4%
    6 Month
    +77.8%
    +77.8%
    1 Year
    +73.1%
    +73.1%

    More News

    Read More
    News headline image
    Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    News headline image
    LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Lisata Shares Nearly Double On Buyout Offer: Here Are The Details ↗
    Via Stocktwits
    Topics Workforce
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss ↗
    Via Chartmill
    News headline image
    Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Lisata Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Lisata Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Lisata Therapeutics, Inc. - Common Stock trade on?
    Lisata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lisata Therapeutics, Inc. - Common Stock?
    The ticker symbol for Lisata Therapeutics, Inc. - Common Stock is LSTA on the Nasdaq Stock Market
    What is the current price of Lisata Therapeutics, Inc. - Common Stock?
    The current price of Lisata Therapeutics, Inc. - Common Stock is 4.570
    When was Lisata Therapeutics, Inc. - Common Stock last traded?
    The last trade of Lisata Therapeutics, Inc. - Common Stock was at 01/27/26 04:00 PM ET
    What is the market capitalization of Lisata Therapeutics, Inc. - Common Stock?
    The market capitalization of Lisata Therapeutics, Inc. - Common Stock is 276.64M
    How many shares of Lisata Therapeutics, Inc. - Common Stock are outstanding?
    Lisata Therapeutics, Inc. - Common Stock has 277M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.